Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration

Neuropsychopharmacology

Volumn 38, Issue 7, 2013, Pages 1264-1275

  Mello, Nancy K ^a   Fivel, Peter A ^a   Kohut, Stephen J ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

buspirone; nicotine; nicotine addiction; nicotinecocaine; polydrug abuse model; preclinical studies

Indexed keywords

BUSPIRONE; COCAINE; NICOTINE; PROLACTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE LUMEN CATHETER; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEDATION; STEADY STATE;

ANIMALS; ANTI-ANXIETY AGENTS; BUSPIRONE; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MACACA MULATTA; NICOTINE; NICOTINIC AGONISTS; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 84878549429     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.25     Document Type: Article

References (82)

1. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA (2003). Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28: 1272-1280.
2. Bechtholt AJ, Mark GP (2002). Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats. Psychopharmacology (Berl) 162: 178-185.
3. Benowitz NL (2009). Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49: 57-71.
4. Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR et al (2012). Modification of cocaine self-administration by buspirone (Buspars): potential involvement of D3 and D4 dopamine receptors. Int J Neuropsychopharmacol 25: 1-14.
5. Budney AJ, Higgins ST, Hughes JR, Bickel WK (1993). Nicotine and caffeine use in cocaine-dependent individuals. J Subst Abuse 5: 117-130.
6. Butelman ER, Harris TJ, Kreek MJ (1999). Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology (Berl) 147: 73-80.
7. Callahan PM, Cunningham KA (1997). Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology 36: 373-381.
8. CDC (2002). Cigarette smoking among adults-United States. 2000. Morb Mortal Wkly Rep 51: 642-645.
9. CDC (2004). Adult cigarette smoking in the United States: current estimates. National Center for Chronic Disease Prevention and Health Promotion Tobacco Information and Prevention Source (TIPS) 15: 20-58.
10. Centers for Disease Control and Prevention (CDC) (2005). Annual smoking-attributable mortality, years of potential life lost and productivity losses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep 54: 625-628.
11. Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Meyer WJI, Van Vunakis H (1995). A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high-and low-anxiety smokers. J Clin Pharmacol 15: 182-191.
12. Corrigall WA, Coen KM, Adamson KL (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653: 278-284.
13. DiChiara G (2000). Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393: 295-314.
14. Dockens RC, Salazar DE, Fulmore IE, Wehling M, Arnold ME, Croop R (2006). Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 46: 1308-1312.
15. Dockens RC, Tran AQ, Zeng J, Croop R (2007). Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans. Biopharm Drug Dispos 28: 393-402.
16. Farid P, Abate MA (1998). Buspirone use for smoking cessation. Ann Pharmacother 32: 1362-1364.
17. Fivel PA (2011). Computer-controlled drug doses for IV drug selfadministration. Exp Clin Psychopharmacol 19: 131-133.
18. Freeman KB, Woolverton WL (2009). Self-administration of cocaine and nicotine mixtures by rhesus monkeys. Psychopharmacology (Berl) 207: 99-106.
19. Gammans RE, Mayol RF, LaBudde JA (1986). Metabolism and disposition of buspirone. Am J Med 80: 41-51.
20. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL (2000). Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38: 432-437.
21. Gold LH, Balster RL (1992). Effects of buspirone and gepirone on i.v. cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 108: 289-294.
22. Goldberg SR, Spealman RD, Goldberg DM (1981). Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214: 573-575.
23. Gotti C, Clementi F (2004). Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363-396.
24. Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M (2007). Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74: 1102-1111.
25. Han ZY, Le Novere N, Zoli M, Hill JAJ, Champtiaux N, Changeux JP (2000). Localization of nAChR subunit mRNAs in the brain of Macaca mulatta. Eur J Neurosc 12: 3664-3674.
26. Han ZY, Zoli M, Cardona A, Bourgeois JP, Changeux JP, Le Novere N (2003). Localization of [3H]Nicotine, [3H]Cytisine, [3H]Epibatidine, and [125I]a-Bungarotoxin binding sites in the brain of Macaca mulatta. J Comp Neurol 461: 49-60.
27. Heidbreder CA, Gardner EL, Xi Z-X, Thanos PK, Mugnaini M, Hagan JJ et al (2005). The role of central dopamine D3 receptors in drug addiciton: a review of pharmacological evidence. Brain Res Rev 49: 77-105.
28. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 1187: 4-34.
29. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML (2005). Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55: 281-299.
30. Hilleman DE, Mohiuddin SM, Del Core MG, Sketch Sr MH (1992). Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 152: 350-352.
31. Hilleman DE, Mohiuddin SM, Delcore MG (1994). Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. J Clin Pharmacol 34: 222-224.
32. Homberg JR, Arends B, Wardeh G, Raaso HS, Schoffelmeer AN, de Vries TJ (2004). Individual differences in the effects of serotonergic anxiolytic drugs on the motivation to self-administer cocaine. Neuroscience 128: 121-130.
33. Horger BA, Giles MK, Schenk S (1992). Preexposure to amphetamine and nicotine predisposes rats to self-administer a low dose of cocaine. Psychopharmacology (Berl) 107: 271-276.
34. ILAR-NRC (1996). Guide for the Care and Use of Laboratory AnimalsNational Academy Press: Washington, DC125.
35. Khaled MATM, Araki KF, Li B, Coen KM, Marinelli PW, Varga J et al (2010). The selective dopamine D3 receptor antagonist SB-277011A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol 13: 181-190.
36. Kuhar MJ, Ritz MC, Boja JW (1991). The dopamine hypothesis of the reinforcing properties of cocaine. TINS 14: 299-302.
37. Kula NS, Baldessarini RJ, Kebabian JW, Neumeyer JL (1994). S-()-aporphines are not selective for human D3 dopamine receptors. Cell Mol Neurobiol 14: 185-191.
38. Le Foll B, Goldberg SR, Sokoloff P (2005a). D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49: 525-541.
39. Le Foll B, Goldberg SR, Sokoloff P (2007a). Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 16: 45-57.
40. Le Foll B, Schwartz J-C, Sokoloff P (2000). Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 15: 140-146.
41. Le Foll B, Sokoloff P, Stark H, Goldberg SR (2005b). Dopamine D3 ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminativestimulus or antidepressant-like effects. Neuropsychopharmacol 30: 720-730.
42. Le Foll B, Wertheim C, Goldberg SR (2007b). High reinforcing efficacy of nicotine in non-human primates. PloS One 2: e230.
43. Line SW (1987). Environmental enrichment for laboratory primates. JAVMA 190: 854-859.
44. Mello NK (2005). Marian W. Fischman Memorial Lecture (2004). Evaluation of drug abuse treatment medications: Concordance between clinical and preclinical studies. In: Dewey WL (eds). Problems of Drug Dependence 2004: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. US Department of Health and Human Services, National Institutes of Health: Bethesda, MD, pp 82-104.
45. Mello NK, Fivel PA, Kohut SJ, Bergman J (2012). Effects of chronic buspirone treatment on cocaine self-administration. Neuropsychopharmacology 38: 455-467.
46. Mello NK, Negus SS (1996). Preclinical evaluation of pharmacotherapies for treatment of cocaine and opiate abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424.
47. Mello NK, Negus SS, Lukas SE, Mendelson JH, Sholar JW, Drieze JM (1995). A primate model of polydrug abuse: Cocaine and heroin combinations. J Pharmacol Exp Ther 274: 1325-1337.
48. Mello NK, Newman JL (2011). Discriminative and reinforcing stimulus effects of nicotine, cocaine, and cocainenicotine combinations in rhesus monkeys. Exp Clin Psychopharmacol 19: 203-214.
49. Muller CP, Carey RJ, Huston JP, De Souza Silva MA (2007). Serotonin and psychostimulant addiction: focus on 5-HT1Areceptors. Prog Neurobiol 81: 133-178.
50. Negus SS, Mello NK (2003a). Effects of chronic d-amphetamine treatment on cocaine-and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacol 167: 324-332.
51. Negus SS, Mello NK (2003b). Effects of chronic d-amphetamine treatment on cocaine-and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alc Depend 70: 39-52.
52. Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P (2012). Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 84: 992-890.
53. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R et al (2009). N-(4-(4-(2,3-Dichloro-or2-methoxyphenyl)piperazin-1-yl)butyl) heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem 52: 2559-2570.
54. Newman AH, Grundt P, Nader MA (2005). Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48: 3663-3679.
55. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L et al (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355: 245-256.
56. Nisell M, Nomikos GG, Svensson TH (1994). Systemic nicotineinduced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44.
57. Pak AC, Ashby CR, Heidbreder CA, Pilla M, Gilbert JG, Xi X-Z et al (2006). The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9: 1-18.
58. Paterson D, Nordberg A (2000). Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111.
59. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM et al (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
60. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C (1997). Common neural substrates for the addictive properties of nicotine and cocaine. Science 275: 83-86.
61. Pierce RC, Kumaresan V (2006). The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30: 215-238.
62. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY et al (2000). Pharmacological actions of a novel, highaffinity, and selective human dopamine D3 receptor antagonist, SB-277011A. J Pharmacol Exp Ther 294: 1154-1165.
63. Reid MS, Mickalian JD, Delucchi KL, Berger SP (1999). A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 20: 297-307.
64. Reid MS, Mickalian JD, Delucchi KL, Hall SM, Berger SP (1998). An acute dose of nicotine enhances cue-induced cocaine craving. Drug Alc Depend 49: 95-104.
65. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
66. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1988). Cocaine selfadministration appears to be mediated by dopamine uptake inhibition. Prog Neuropsychopharmacol Biol Psychiatry 12: 233-239.
67. Roll JM, Higgins ST, Budney AJ, Bickel WK, Badger GJ (1996). A comparison of cocaine-dependent cigarette smokers and nonsmokers on demographic, drug use and other characteristics. Drug Alcohol Depend 40: 195-201.
68. Roll JM, Higgins ST, Tidey J (1997). Cocaine use can increase cigarette smoking: evidence from laboratory and naturalistic settings. Exp Clin Psychopharmacol 5: 263-268.
69. Rose JE (2007). Multiple brain pathways and receptors underlying tobacco addiction. Biochem Pharmacol 74: 1263-1270.
70. Ross JT, Corrigall WA, Heidbreder CA, LeSage MG (2007). Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressiveratio schedule in rats. Eur J Clin Pharmacol 559: 173-179.
71. Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV (1996). Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 60: 568-575.
72. Spiller K, Xi XZ, Peng XQ, Newman AH, Ashby CRJ, Heidbreder C et al (2008). The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl) 196: 533-542.
73. Stemp G, Ashmeade T, Branch CL, Hadley MS, Hunter AJ, Johnson CN et al (2000). Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 43: 1878-1885.
74. Stolerman IP, Shoaib M (1991). The neurobiology of tobacco addiction. Trends Pharmacol Sci 12: 467-473.
75. Sziraki I, Sershen H, Benuck M, Hashim A, Laitha A (1999). Differences in receptor system participation between nicotineand cocaine-induced dopamine overflow in nucleus accumbens. NY Acad Sci 877: 800-802.
76. Tallman F, Primus RJ, Brodbeck R, Cornfield L, Meade R, Woodruff K et al (1997). I. NGD 94-1: Identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther 282: 1011-1019.
77. Watkins SS, Koob GF, Markou A (2000). Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2: 19-37.
78. Weerts EM, Fantegrossi WE, Goodwin AK (2007). The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol 15: 309-327.
79. Winhusen T, Brady KT, Stitzer M, Woody G, Lindblad R, Kropp F et al (2012). Evaluation of buspirone for relapseprevention in adults with cocaine dependence: an efficacy trial conducted in the real world. Contemp Clin Trials 33: 993-1002.
80. Wong H, Dockens RC, Pajor L, Yeola S, Grace JEJ, Stark AD et al (2007). 6-hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine 1A receptor occupancy in rats. Drug Metab Dispos 35: 1387-1392.
81. Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z et al (2012). Blockade of dopamine D4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology 37: 685-696.
82. Zernig G, O'Laughlin IA, Fibiger HC (1997). Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens. Eur J Pharmacol 337: 1-10.